Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) General Information

Description

Worldwide license and commercialization rights to autologous anti-cd19 t-cell therapy product located in Tianjin City, China. The asset is widely expressed during all phases of b-cell development and a validated target for b-cell driven hematological malignancies in children and adults with relapsed B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Building 5, No.8, Haitai Development 3rd Avenue
  • Huayuan Industrial Zone
  • Tianjin
  • China
Primary Industry
Buildings and Property
Other Industries
Drug Delivery
Pharmaceuticals
Corporate Office
  • Building 5, No.8, Haitai Development 3rd Avenue
  • Huayuan Industrial Zone
  • Tianjin
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)‘s full profile, request access.

Request a free trial

Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)‘s full profile, request access.

Request a free trial

Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) FAQs

  • Where is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) headquartered?

    Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is headquartered in Tianjin, China.

  • What industry is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) in?

    Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s primary industry is Buildings and Property.

  • Is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) a private or public company?

    Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is a Private company.

  • What is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s current revenue?

    The current revenue for Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is .

  • Who are Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s investors?

    Juventas (Drug Discovery) has invested in Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China).

  • When was Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) acquired?

    Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) was acquired on 03-Dec-2019.

  • Who acquired Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)?

    Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) was acquired by CASI Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process